2018
Race, Risk, and Willingness of End-Stage Renal Disease Patients Without Hepatitis C Virus to Accept an HCV-Infected Kidney Transplant
McCauley M, Mussell A, Goldberg D, Sawinski D, Molina RN, Tomlin R, Doshi SD, Abt P, Bloom R, Blumberg E, Kulkarni S, Esnaola G, Shults J, Thiessen C, Reese PP. Race, Risk, and Willingness of End-Stage Renal Disease Patients Without Hepatitis C Virus to Accept an HCV-Infected Kidney Transplant. Transplantation 2018, 102: e163-e170. PMID: 29346260, DOI: 10.1097/tp.0000000000002099.Peer-Reviewed Original ResearchConceptsHepatitis C virusHCV cure ratesCure rateC virusUninfected kidneyEnd-stage renal disease patientsHCV-negative patientsPrior transplant recipientsRenal disease patientsHigh cure ratesEffective antiviral treatmentKidney recipientsTransplant recipientsKidney transplantMost patientsOlder patientsAntiviral treatmentWhite patientsDeceased donorsAllograft qualityFuture trialsBlack raceDisease patientsPatient acceptanceYoung donors
2006
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT
Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox M, Orsucci L, Fabbri A, Frezzato M, Voso M, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Annals Of Oncology 2006, 18: 346-350. PMID: 17071937, DOI: 10.1093/annonc/mdl388.Peer-Reviewed Original ResearchConceptsHCV-positive patientsMarginal zone B-cell lymphomaHCV-negative patientsEvent-free survivalHCV infectionMarginal zone lymphomaB-cell lymphomaOverall survivalHigh prevalenceMost HCV-positive patientsHepatitis C virus infectionC virus infectionBone marrow involvementOverall response rateMALT sitesHCV serostatusAdvanced diseasePresenting featuresHCV serologyMarrow involvementOrgan involvementPoor OSAntiviral treatmentIndolent courseHistological diagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply